Harvard Bioscience Inc. (HBIO)
HBIO trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1123494/000117184326001548/0001171843-26-001548-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | HBIO on Nasdaq |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | 2000 |
| SEC CIK | 0001123494 |
| SEC industry code | Laboratory Analytical Instruments |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $86.5M |
| Net income | -$56.7M |
| Operating income | -$48.6M |
| Net margin | -65.5% |
| Operating margin | -56.1% |
| Revenue growth | -8.1% |
| Cash | $8.6M |
| Total assets | $80.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Although management has identified the existence of adverse conditions with respect to its liquidity, including recurring net losses, negative cash flows from operating activities and a decline in cash and cash equivalents, it has concluded that these conditions, when considered in the aggregate, do not raise substantial doubt about the Company's ability to continue as a going concern within twelve months from the is" | 10-Q 2026-11-10 |
| Cash and burn | $4.9M cash; operating cash flow -$170K a quarter. | Report 2026-09-30 |
| Shares outstanding | 4,573,080 (2026-11-03); 44,579,665 a year earlier; 42,688,246 three years earlier. 1y figure adjusted for splits (1-for-10 overall); 3y figure adjusted for splits (1-for-10 overall). | Cover page 2026-11-03 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2026-03-16 | Source 2026-03-16 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-01-30 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton LLP, Hartford, Connecticut, United States | PCAOB Form AP 2026-03-19 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $202K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $22.2M | -$2.6M | -$248K | $4.9M | $37.2M | $89.4M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $22.7M | -$2.9M | $325K | $6.5M | $36.7M | $87.8M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $20.8M | -$3.4M | -$662K | $7.1M | $36.2M | $85.5M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $23.7M | -$2.8M | -$96K | $8.6M | $35.9M | $86.5M | 10-K 2026-03-13 |
| Q3 2025 2025-09-30 | $20.6M | -$1.2M | $1.1M | $6.8M | $34.0M | $87.4M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $20.4M | -$2.3M | $2.8M | $7.4M | $34.9M | $88.8M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $21.8M | -$50.3M | $3.0M | $5.5M | $36.4M | $91.4M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $24.6M | $18K | $1.7M | $4.1M | $37.0M | $94.1M | 10-K 2026-03-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B3 | 424B3 | 2026-02-09 |
| Latest annual report FORM 10-K | 10-K | 2026-03-13 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-10 |
| Latest current report FORM 8-K | 8-K | 2026-11-10 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +12.3% |
| 1 month | +13.5% |
| 3 months | +40.8% |
| Year to date | +40.1% |
| 1 year | +61.9% |
| From 52-week high | -3.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RPID | Rapid Micro Biosystems Inc. | $0.7400 | +13.67% | $37.1M |
| PRPO | Precipio Inc. | $19.96 | -9.81% | $35.8M |
| EYPT | EyePoint Inc. | $0.3076 | +0.52% | $35.0M |
| SEER | Seer Inc. | $1.48 | -5.73% | $82.6M |
| CIRC | Circle8 Group Inc. | $0.1702 | -7.30% | $20.0M |
| BNGO | Bionano Genomics Inc. | $0.9400 | -6.00% | $13.1M |
| QTRX | Quanterix Corporation | $2.84 | -3.07% | $134.8M |
| ASTC | Astrotech Corporation (DE) | $3.76 | -10.48% | $8.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier